{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-092761","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.327057+00:00","generated_at":"2026-06-07T18:42:19.663224+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Silo Pharma shareholders approve 80% authorized share reduction and equity plan at annual meeting","bullets":["Four directors elected: Weisblum, Linsley, Muñoz, Pavell (1.45M-1.45M for each).","Amended 2020 Omnibus Equity Incentive Plan approved (1.43M for, 97,553 against, 11,988 abstain).","Authorized common shares reduced from 500M to 100M (1.52M for, 2,648 against, 10,000 abstain).","Ratification of Salberg & Company as auditor approved (1.51M for, 189 against, 66,435 abstain).","Vote on reincorporation to Nevada adjourned to December 11, 2023; results to be filed later."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-092761","json":"https://secwatch.observer/filing/0001213900-23-092761.json","markdown":"https://secwatch.observer/filing/0001213900-23-092761.md","text":"https://secwatch.observer/filing/0001213900-23-092761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023092761/0001213900-23-092761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023092761/ea189483-8k_silo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:42:19.663224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e72605cdf9123872c41b78090af5b36eff779cd","claim":"Silo Pharma, Inc. shareholders approved Election of four directors at the 2023-12-04 meeting.","evidence_excerpt":"The result of the votes to elect the four directors was as follows: Directors For Withheld Broker Non-Votes Eric Weisblum 1,448,375 88,266 40,875 Wayne D. Linsley 1,406,716 129,925 40,875 Dr. Kevin Muñoz 1,422,577 114,064 40,875 Dr. Jeff Pavell 1,448,425 88,216 40,875","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023092761/0001213900-23-092761-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-04"}],"fact_type":"shareholder_vote"},{"claim_id":"8a378a148e7befe6ac7f0b57d6be5d7c300572a1","claim":"Silo Pharma, Inc. shareholders approved Amendment to Certificate of Incorporation to decrease authorized shares from 500,000,000 to 100,000,000 at the 2023-12-04 meeting.","evidence_excerpt":"The result of the votes to approve the Share Decrease Proposal was as follows: For Against Abstain Broker Non-Vote 1,523,993 2,648 10,000 40,875","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023092761/0001213900-23-092761-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-04"}],"fact_type":"shareholder_vote"},{"claim_id":"d5e7524b14511e8537f0d52b835d812f1b5dd5b4","claim":"Silo Pharma, Inc. shareholders approved Ratification of appointment of Salberg & Company, P.A. as independent public accountant at the 2023-12-04 meeting.","evidence_excerpt":"The result of the votes to approve Salberg & Company, P.A. was as follows: For Against Abstain 1,510,892 189 66,435","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023092761/0001213900-23-092761-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-04"}],"fact_type":"shareholder_vote"},{"claim_id":"f7a30874079bc830ecdc4d315ed0dace236cc024","claim":"Silo Pharma, Inc. shareholders approved Approval of Amended and Restated 2020 Omnibus Equity Incentive Plan at the 2023-12-04 meeting.","evidence_excerpt":"The result of the votes to approve the Amended 2020 Plan was as follows: For Against Abstain Broker Non-Vote 1,427,100 97,553 11,988 40,875","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023092761/0001213900-23-092761-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-04"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}